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Abstract
Ovalbumin (OVA)-sensitized BALB/c mice were i.n. instilled with recombinant TNF-
related apoptosis inducing ligand (TRAIL) 24 hours before OVA challenge. The
total number of leukocytes and the levels of the chemokine CXCL-1/KC significantly
increased in the bronchoalveolar lavage (BAL) fluids of allergic animals with respect
to control littermates, but not in the BAL of mice i.n. pretreated with recombinant
TRAIL before OVA challenge. In particular, TRAIL pretreatment significantly
reduced the BAL percentage of both eosinophils and neutrophils. On the other
hand, when TRAIL was administrated simultaneously to OVA challenge its effect on
BAL infiltration was attenuated. Overall, the results show that the i.n. pretreatment
with TRAIL down-modulated allergic airway inflammation.
Introduction
Asthma is a common syndrome with increasing prevalence in both children and
adults [1]. Despite the increasing prevalence and socioeconomic burden, the
underlying pathophysiology remains poorly defined in a large percentage of
asthmatics. Asthma is indeed a complex syndrome with many clinical phenotypes,
usually characterized by chronic airway inflammation associated with airway
obstruction and hyperresponsiveness (AHR) [1]. Airway inflammation is thought
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to play an important role in mediating airflow obstruction and the inflammatory
changes associated with asthma are usually characterized by an accumulation of
eosinophils, T lymphocytes, mast cells and neutrophils in the airway walls, lung
tissue and airway lumen [1]. TNF-related apoptosis inducing ligand (TRAIL) is an
important immunomodulatory cytokine and a series of studies have addressed the
potential role of the TRAIL/TRAIL-receptor system in the context of asthma,
mainly in animal models [2–9]. While some studies, mainly based on the use of
TRAIL-/- knock out mouse models [4, 6], point on a pro-inflammatory role of
endogenous TRAIL, a more recent study has demonstrated that recombinant
TRAIL administration might rather plays a role in the resolution phase of asthma,
by promoting apoptosis of infiltrating leukocytes [9]. These conflicting data are
consistent with in vitro and in vivo studies demonstrating a dual role for TRAIL,
which can either function as a pro- or anti-inflammatory cytokine targeting
inflammatory cells, participating in either the initiation or in the resolution of
inflammatory/immune responses, depending on the context [5, 10, 11].
Based on our experience in characterizing the role of the TRAIL/TRAIL-
receptor system in different physio-pathological contexts [11–15], in the present
study we have evaluated the effect(s) of intranasal treatment with recombinant
TRAIL in a mild allergen-induced airway inflammation model represented by
ovalbumin (OVA)-sensitized BALB/c mice [16–18].
Material and Methods
Experimental allergen-induced airway inflammation model
Pathogen-free female BALB/c mice (4- to 6-weeks old) were purchased from
Charles River Laboratories Inc. (Milano, Italy). Mice were housed in a controlled
environment and maintained with ad libitum food and water. All animal
procedures were used to minimize animal pain and suffering. All the experimental
procedures were performed in strict accordance with the recommendations in the
Guide for the Care and Use of the Laboratory Animals of the National Institutes
of Health and in compliance with the European (86/609/EEC) and Italian
(D.L.116/92) laws. The protocols for mice experimentation were approved by the
Institutional Animal Care and Use Committee of the Cluster in Biomedicine
(CBM) of the Area Science Park of Trieste and by the Italian Ministry of Health
(DM 17/2001-A dd. 02/02/2011).
For the experimental allergen-induced airway inflammation model, BALB/c
mice were sensitized and challenged by using OVA (Sigma-Aldrich, St Louis, MO)
as allergen as previously described [18]. In particular, mice were treated on day 0
and day 21 with 50 mg of OVA in a volume of 0.2 ml PBS (Sigma-Aldrich) via
intraperitoneal (i.p.) injection. On day 28 and day 29 post-immunization, mice
were challenged with intranasal (i.n.) instillation of 250 mg OVA diluted in 25 ml
of PBS. All i.n. procedures were performed under mild 2% isoflurane, 2 L/min
oxygen anesthesia of the mice. Healthy age and gender matched BALB/c mice
were used as healthy controls and underwent to the same schedule of injection
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with control vehicle (PBS). At different days, blood samples were collected from
healthy controls and asthmatic mice for IgE quantification and at day 32 mice
were sacrified with an overdose of isoflurane. Blood was collected and lungs were
fixed in 10% phosphate-buffered formalin for 24 hours followed by immersion in
70% ethanol, embedded in paraffin. Three mm thick lung sections containing
main stem bronchi were stained with hematoxylin and eosin, as previously
reported [18], before analyses for the presence of bronchial architecture
remodeling and inflammation. To semi-quantitatively evaluate the bronchial
architecture, at least 40 airways were scored for each sample and assigned regular
versus distorted (irregular arrangement and thickening of the epithelial layer)
lining epithelia. The ratio between distorted/regular epithelia was then calculated
for each sample. In parallel, semi-quantitative evaluation of inflammation was
carried out by assigning the following arbitrary scores: 0, no inflammatory
infiltrates; 0.5, inflammatory infiltrates present in up to 1/3 of lung parenchima; 1,
inflammatory infiltrates present in more than 1/3 of lung parenchima.
TRAIL imaging and treatment
Purified human recombinant TRAIL was prepared and tested for the absence of
endotoxin by using the ToxinSensor chromogenic LAL endotoxin assay kit
(GenScript, Piscataway, NJ), as previously described [19, 20]. For in vivo/ex vivo
imaging experiments, recombinant TRAIL was labeled with N-hydroxysucci-
nimmide ester of the cyanine 5.5 (Amersham Pharmacia Biotech) to form Cy5.5-
TRAIL [21]. Mice were anesthetized with isoflurane at 1.8–2.0 volume % (Sigma),
shaved in the abdomen to avoid laser scattering caused by fur, placed in the small-
animal time-domain imager Optix MX2 preclinical NIRF-imager (Advanced
Research Technologies, Montreal, CA) and maintained under vaporized
isoflurane for the entire imaging session. Two-dimensional regions of interest
were selected, and laser power, integration time (repetition time of the excitation
per raster point) and scan step size were optimized according to the emitted
signal. A blank image was acquired before i.n. administration of Cy5.5-TRAIL to
record background signal intensity. After i.n. Cy5.5-TRAIL-instillation (20 mg in
25 ml PBS) the animals were monitored at multiple time points. In all imaging
experiments, a 670 nm pulsed laser diode with a repetition frequency of 80 MHz
and a time resolution of 12 ps light pulse was used for excitation. Fluorescence
emission was collected at 700 nm. For ex vivo imaging tissue analysis, the last in
vivo whole-body imaging session was followed by euthanasia of animals and the
explanted lungs were collected, washed in PBS (Sigma-Aldrich) and analyzed with
the same Optix system. Optical imaging results were analyzed by reporting
fluorescence intensity values in normalized counts (NC) representing the photon
count for unit excitation laser power and unit exposure time, allowing
comparison among different images. For recombinant TRAIL treatments, mice
received i.n. instillation of 20 mg of recombinant TRAIL resuspended in 50 ml PBS
either before or at the time of OVA challenges.
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Bronchoalveolar lavage (BAL) fluid analyses
BAL collection was performed at the time of sacrifice by injection of 1 ml of PBS
through a tracheal cannula inserted into the lung. The recovered solution was
then centrifuged for 10 minutes at 4006g at 4 C˚, cell-free supernatants were
collected and stored at 280 C˚ in single-use aliquots for cytokines/chemokines
evaluation while the cell pellets were resuspended in 1 ml of PBS and used for cell
counts, cytospin preparation/visualization by May-Giemsa staining and multi-
parametric flow-cytometry. Cell count and viability was determined by Trypan
blue dye exclusion, as previously described [22], while the degree of apoptosis was
quantified by Annexin V-FITC/propidium iodide (PI) double staining
(Immunotech, Marseille, France) followed by flow cytometry analysis, as
previously detailed [23, 24].
For multiparametric FACS analyses, an aliquot of the single-cell suspensions
obtained from BAL was resuspended in PBS, 0.5% fetal bovine serum (FBS; Gibco
Life Technologies, Grand Island, NY) according to standard protocols and used
for cell populations’ characterization after staining with the following fluor-
ochrome-conjugated monoclonal antibodies: anti-muCD3e (Clone 145-2C11),
anti-muCD19 (Clone 1D3), anti-muMHCII (clone 2G9), anti-muGr1 (Clone
RB6-8C5) and anti-muCD11c (Clone HL3) (all from BD Pharmingen, San Jose,
CA) and anti-muCCR3 (Clone 2.4G2, R&D Systems, Minneapolis, MN). The
purified anti-CD16/CD32 antibody blocking reagent (Clone 2.4G2, BD
Pharmingen) was also added to the cells for blocking of Fc receptor. Cells were
incubated for 20 minutes at 4 C˚, washed in PBS and fixed in PBS-1%
formaldehyde (Sigma-Aldrich) and 0.5% FBS. Data were acquired in a FACS
ARIA II (BD Bioscience), analyzed with FlowJo software (TreeStar, Ashland, OR).
Biochemical measures
Total IgE were measured in murine serum samples by using the Mouse IgE Single
Plex Magnetic Bead Kit (Merck Millipore, Billerica, MA). Levels of recombinant
human TRAIL and soluble murine TRAIL were measured in serum samples by
commercially available ELISA kits specific for human TRAIL (R&D Systems) and
murine TRAIL (Cloud-Clone Corp., Houston, TX), respectively in accordance
with the manufacturer’s instructions. Samples were analyzed in duplicate with an
ELISA reader at 450 nm, as previously described [25].
Levels of murine cytokines/chemokines were measured in BAL fluids using the
Multiplex MILLIPLEX MAP Mouse Cytokine/Chemokine Magnetic Bead Panel
Kit (Merck Millipore) that allowed the simultaneous quantification of the
following 32 murine cytokines/chemokines: Eotaxin, G-CSF, GM-CSF, IFN-c, IL-
1a, IL-1b, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70),
IL-13, IL-15, IL-17, IP-10, KC, LIF, LIX, MCP-1, M-CSF, MIG, MIP-1a, MIP-1ß,
MIP-2, RANTES, TNF-a, VEGF. All samples were run in duplicate in accordance
with the manufacturer’s instructions.
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Quantitative RT-PCR
Total RNA was extracted from murine lung tissues using the Qiagen RNeasy Plus
mini kit (Qiagen, Hilden, Germany) according to the supplier’s instructions, and
further treated with the Qiagen RNase-Free DNase Set (Qiagen) to remove
genomic DNA. For the integrity measurement, 4 ml of the total RNA were
analyzed on an Agilent Cary 60 UV-VisSpectrophotometer (Agilent Technologies
Inc., Santa Clara, CA). Total RNA was transcribed into cDNA and amplified using
the Express One-Step Superscript qRT-PCR Kit (Invitrogen, Carlsbad, CA).
Analysis of murine CXCL1 (KC), CCL20 and Mideline-1 (MID-1) was carried out
with validated TaqMan Gene Expression Assays specific PCR primers sets
(Invitrogen) [26]. All samples were run in triplicate using the real time thermal
analyzer Rotor-Gene 6000 (Corbett, Cambridge, UK). Expression values were
normalized to the housekeeping murine gene POLR2A amplified in the same
sample.
Statistical analysis
Descriptive statistics were calculated. For each set of experiments, values were
reported as means ¡ standard deviation (SD) and box plots were used to show
the median, minimum and maximum values, and 25th to 75th percentiles. The
results were analyzed by using the Mann-Whitney rank-sum test and statistical
significance was defined as p,0.05. All statistical analyses were performed with
SPSS Statistic 20 software (SPSS Inc., Chicago, IL).
Results
In vivo biodistribution of recombinant TRAIL upon intranasal
instillation
The primary aim of this study was to explore the potential of TRAIL as
pharmacological approach aiming to modulate the inflammatory process
associated to allergen-induced airway inflammation. To this end, in a first set of
experiments we evaluated the biodistribution of recombinant TRAIL after i.n.
delivery by using an in vivo/ex vivo imaging approach. A single i.n. instillation of
Cy5.5-labelled TRAIL (20 mg/instillation) was administered to BALB-c mice and
whole-body imaging was performed acquiring fluorescence intensity images up to
72 hours post-instillation. As shown in Fig. 1A, soon after i.n. instillation, the in
vivo analysis displayed the highest fluorescence signal in the upper respiratory
tract, while after 2 hours the highest signal resulted associated with gastro-
intestinal tract and tended to decrease over time. The ex vivo analysis of the
explanted lungs, performed at different times (2, 24, 48 and 72 hours) after
TRAIL-Cy5.5 i.n. delivery, showed a significant and persistent fluorescent signal in
the lung that was still significantly detectable 72 hours after i.n. instillation as
compared to controls, which showed barely detectable fluorescence (Fig. 1B).
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Fig. 1. In vivo biodistribution of recombinant TRAIL. Mice were i.n. instilled with recombinant TRAIL
(20 mg). In A, the distribution of the labeled Cy5.5-TRAIL was recorded at the indicated time intervals by whole
body scans in six mice. Results of one representative mouse before (control) and after i.n. instillation are
shown. In B, ex vivo representative images of lungs isolated from mice sacrificed at the indicated time points
after i.n. instillation of Cy5.5-TRAIL compared to a representative lung isolated from a control mouse (i.n.
instillation with control vehicle). In C, after i.n. instillation a time course detection of circulating recombinant
human TRAIL was assessed by ELISA performed on murine sera samples. Results are reported as mean¡
SD of 6 mice.
doi:10.1371/journal.pone.0115387.g001
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Moreover, in order to determine the presence of recombinant TRAIL also at
systemic level, we performed a time course analysis after the i.n. delivery, by
quantifying recombinant human TRAIL in serum samples using a specific ELISA
for human TRAIL detection. As shown in Fig. 1C, recombinant human TRAIL
was undetectable (below the detection limit: 15.6 pg/ml) at baseline (time 0),
became detectable in serum samples at 24 hours (mean ¡ SD: 852.5¡581.7 pg/
ml) after i.n. instillation and progressively decreased thereafter (48 hours, mean
¡ SD: 105.9¡57.7 pg/ml; 72 hours, mean ¡ SD: 43.2¡36.1 pg/ml) becoming
undetectable at 96 hours. In parallel, the mean baseline levels of soluble murine
TRAIL, assessed at all time point examined by using a murine-specific TRAIL
ELISA assay, were 727¡234 pg/ml.
Pretreatment with recombinant TRAIL attenuates allergen-
induced airway inflammation
OVA-mediated airway inflammation was induced in mice with two rounds of
OVA sensitization (50 mg administered by i.p. injection on days 0 and 21)
followed by two rounds of OVA challenge (250 mg administered by i.n. instillation
on days 28 and 29) (Fig. 2A). The development of allergen-induced inflammation
in OVA-treated mice was mainly documented by evaluating the presence/levels of
circulating IgE in comparison to control mice. Indeed, the exposure of sensitized
mice to inhaled antigen elicits a significant (p,0.01) elevation of serum IgE after
OVA challenge (Fig. 2B) coupled to thickness of airway epithelial cells (Fig. 2C).
In order to evaluate the potential ability of TRAIL in modulating allergen-
induced airway inflammation, mice (n516/group) were either treated with
control vehicle (PBS) or with recombinant TRAIL (20 mg via i.n.) on day 27 and
28, before OVA challenges (Fig. 3A). In parallel, as controls, healthy mice (n56)
were instilled with recombinant TRAIL, with the same treatment schedule and
protocol. Consistently with the evidence that total cell count in BAL is an
indicator of the inflammatory cell influx into the lung from the surrounding
blood network, we observed an increase in the absolute number of cells recovered
from BAL of OVA-mice at 24 hours post-challenge (median and mean ¡ SD:
3066103 and 2946103¡506103 cells) with a further increased at 72 hours
(median and mean ¡ SD: 3586103 and 3756103¡836103 cells), reaching
significant (p,0.01) differences with respect to the healthy control mice (median
and mean ¡ SD: 2256103 and 2306103¡326103 cells) (Fig. 3B). No
significant effects on BAL total cell count were observed in TRAIL-treated control
healthy mice (median and mean ¡ SD: 2206103 and 2236103¡206103 cells).
Moreover, the nature of the cell populations characterizing BAL samples was
analyzed by multiparametric flow cytometry: according to the FSC/SSC gating,
lymphocytes (T and B) were identified as CD3+ and CD19+; granulocytes were
identified as CD11c-/MHCII-; neutrophils were identified as CD11c-/MHCII-/
Gr1+/CCR3+; eosinophils were identified as CD11c-/MHCII-/Gr1dim/CCR3+;
alveolar macrophages (AM) were identified as CD11c+/MHCIIdim/neg; dendritic
cells (DC) were identified as CD11c+/MHCII+ (Fig. 3C). OVA-mediated airway
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Fig. 2. Establishment of airway inflammation mouse model. Mice were exposed to an OVA ‘‘sensitization
plus challenge’’ protocol. In A, the schedule and the timeline of OVA treatments of BALB/c mice are shown. In
B, the circulating levels of total IgE were determined in serum samples of controls (n516) and OVA-treated
mice (n516), harvested at the indicated experimental time points. Results are expressed as mean¡ SD. In
C, representative hematoxylin and eosin stained sections of lung tissue isolated (at day 32) from either
healthy control or OVA-treated mice. Lungs of OVA-treated mice exhibit airway remodeling and thickness of
epithelial cells (original magnification 40X).
doi:10.1371/journal.pone.0115387.g002
Effect of Recombinant TRAIL on Airway Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0115387 December 15, 2014 8 / 16
Fig. 3. Effect of recombinant TRAIL on OVA-induced airway inflammation. Mice were treated with recombinant TRAIL before OVA challenges and the
cellular influx in the BAL was characterized. In A, the schedule and the timeline of recombinant TRAIL treatments with regard to OVA sensitizations/
challenges of BALB/c mice are shown. At the time of sacrifice (day 32), the circulating levels of total IgE were determined in serum samples of controls, OVA-
and TRAIL+OVA-mice and expressed as fold of modulation with respect to controls (insert). In B, total cell count of cells present in BAL fluids of controls,
OVA- and TRAIL+OVA-mice (n516 mice/group) is shown. Horizontal bars are median, upper and lower edges of box are 75th and 25th percentiles, lines
extending from box are 10th and 90th percentiles; *, P,0.01. Representative images of May-Gru¨nwald Giemsa stained cytospins of BAL cells from each
Effect of Recombinant TRAIL on Airway Inflammation
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inflammation was characterized by a significant increase of eosinophils and
neutrophils in BAL samples, with respect to the healthy control mice (Fig. 3D).
Of note, the prophylactic i.n. treatment with recombinant TRAIL in OVA-
challenged mice while did not significantly affect the OVA-induced IgE up-
regulation (revised Fig. 3A), it was associated to a significant (p,0.01) reduction
in BAL cell counts (Fig. 3B), with a specific decrease of the eosinophilic and
neutrophilic populations compared to OVA-challenged mice (Fig. 3D).
Consistently, histological analysis showed a reduction in TRAIL treated mice of
the morphological features characterizing the OVA-treated mice, such as airway
remodeling and inflammation (Fig. 3E). Of interest, in our experimental model
we found optimal activity of TRAIL in preventing the increase of BAL leukocytes
when TRAIL was i.n. instilled 24 hours before OVA challenges, while the
protective effect was attenuated when recombinant TRAIL and OVA challenge
were administered at the same time (S1A–B Figure).
Pretreatment with TRAIL down-modulates CXCL-1/KC in the
context of allergen-induced airway inflammation
Since it has been recently shown that recombinant TRAIL administration might
participate to the resolution phase of asthma, by promoting apoptosis of
infiltrating leukocytes [9], we next evaluated whether the decreased number of
BAL infiltrating cells in OVA-challenged animals i.n. pretreated with TRAIL
might be due to induction of apoptosis. Our analyses, although characterized by a
high variability from one experiment to the other, did not show significant
differences in the percentage of apoptotic cells between OVA- and TRAIL+OVA-
mice in our experimental model. Thus, in order to further explore potential
mechanisms underlying the effect of TRAIL in this context, we next assessed the
BAL fluid samples for a commercial panel of 32 cytokines and chemokines
involved in the inflammatory process and that might act as biochemical mediators
of the disease (S1 Table). Within the cytokines and chemokines detectable in BAL
samples at day 32, only the release of CXCL-1 (murine keratinocyte-derived
chemokine KC) was significantly (p,0.05) increased in OVA-mice compared to
healthy controls (S1 Table). Of interest, as shown in Fig. 4A, the pretreatment
with recombinant TRAIL significantly decreased (p,0.01) the BAL release of
CXCL-1/KC (median and mean ¡ SD: 40.7 and 44.3¡14.6 pg/ml) compared to
OVA-mice (median and mean ¡ SD: 63.0 and 60.1¡16.9 pg/ml), showing levels
comparable to those measured in healthy control mice. These findings were
confirmed also at transcriptional level by analyzing the lung levels of CXCL-1/KC
experimental group are shown (original magnification, 20X). In C, gating strategy utilized in multiparametric flow cytometry analysis to identify the major BAL
infiltrating cell types. In D, the percentage of eosinophils, neutrophils, lymphocytes, alveolar macrophages (AM) and dendritic cells (DC) in the BAL of OVA-
mice and of TRAIL+OVA-mice is expressed as fold of modulation with respect to the percentages of control healthy mice (set at 1). Results are mean¡ SD.
*, P,0.05 compared to healthy control mice; 1, P,0.05 compared to OVA-mice (Mann-Whitney rank-sum test). In E, blinded semi-quantitative analysis of
histology from Controls, OVA- and TRAIL+OVA-mice was done to evaluate airway remodeling (left panel) and inflammation (right panel), scored as
detailed in the Material and Methods section. Results are derived from at least 3 microscopy fields for each mouse (n58 for each experimental group). Data
are expressed as mean ¡ SD. *, P,0.05 compared to healthy control mice (Mann-Whitney rank-sum test).
doi:10.1371/journal.pone.0115387.g003
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Fig. 4. Effect of recombinant TRAIL on OVA-induced CXCL-1/KC expression. In A, the levels of CXCL-1/
KC in the BAL fluids of Controls, OVA- and TRAIL+OVA-mice were measured by Multiplex assay. In B, the
expression levels of CXCL-1/KC mRNA in lung tissue of Controls, OVA- and TRAIL+OVA-mice were
determined by quantitative RT-PCR. Results from amplifications, done in duplicate, are expressed as arbitrary
units after normalization for the housekeeping gene. In A–B, horizontal bars are median, upper and lower
edges of box are 75th and 25th percentiles, lines extending from box are 10th and 90th percentiles; *, P,0.05
(Mann-Whitney rank-sum test).
doi:10.1371/journal.pone.0115387.g004
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mRNA assessed by real time PCR (Fig. 4B; controls, median and mean ¡ SD:
1.01 and 1.1¡0.4 arbitrary units; OVA-vehicle, median and mean ¡ SD: 1.6 and
1.7¡0.8 arbitrary units; OVA-TRAIL, median and mean ¡ SD: 1.2 and
1.1¡0.3). In parallel, the analysis of the expression levels of CCL20 and MID-1,
proposed as molecular mediators of allergic airways disease [4, 6], confirmed their
significant upregulation in OVA-treated mice compared to controls, but did not
shown any modulation in TRAIL-OVA mice compared to OVA-treated mice (S2
Figure).
Discussion
Previous studies comparing the TRAIL-/- knock out mice with the wild-type
littermates [4, 6, 27] have shown that endogenous TRAIL is involved in the
development of experimental asthma. On the other hand, a recent study published
while this manuscript was in preparation documented a protective role of
exogenous soluble TRAIL in the resolution phase of asthma in a chronic model of
allergen inhalation [9]. In this context, the major findings of our current study
performed on a model of mild asthma induced by OVA are the following: (i) i.n.
pre-treatment with recombinant TRAIL significantly counteracted the increase of
infiltrating leukocytes, and in particular of neutrophils and eosinophils, in BAL of
OVA-treated mice. Of note, when TRAIL administration occurred simultaneously
with OVA challenges, the protective effect of TRAIL was attenuated; (ii) the
reduced levels of BAL leukocytes in TRAIL-pretreated allergic animals were not
accompanied by increased levels of cell apoptosis. In this respect, our data differ
from those of two previous studies which proposed that TRAIL could either
promote eosinophil survival [2] or on the contrary eosinophil apoptosis [9]; (iii)
among the 32 cytokines/chemokines investigated in BAL fluid, only CXCL-1/KC
showed a significant and reproducible increase in OVA-treated allergic mice with
respect to healthy control mice and TRAIL pretreatment completely counteracted
its increase in both BAL and lung RNA samples. Due to the key role of CXCL-1 in
recruiting cellular mediators of inflammation [28–34], the ability of TRAIL to
counteract the increased production of CXCL-1/KC induced by allergen
stimulation likely represents a plausible mechanism accounting for the decreased
infiltration of neutrophils and eosinophils in the BAL of OVA-treated animals.
Certainly, we cannot exclude that other cytokines/chemokines are involved in
mediating the recruitment of neutrophils and eosinophils. However, the specific
chemoattractants, and the order in which they act, might differ depending on the
specific pathological stimulus and/or the different experimental settings, including
the specific biologic assays employed for their detection [27, 31]. Since it is
increasingly recognized that both eosinophils and neutrophils play an important
role in the asthmatic response in mice [35], the ability of TRAIL pretreatment to
down-regulate CXCL-1 and to reduce both eosinophil and neutrophil infiltration
is interesting. In this respect, to strengthen the notion that CXCL-1 plays an
important role in asthma, a recent study have started the investigation of the
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potential clinical benefits of a selective CXCR2 receptor antagonist in patients
with severe asthma [36].
We believe that our current data might contribute to conciliate the
discrepancies between the data of Weckmann et al. [4] and Collison et al.
[5, 6, 27], demonstrating that TRAIL-/- knock out mice show less severe
inflammatory reaction in asthmatic models with respect to TRAIL+/+ littermates,
with those of Faustino et al. [9], suggesting that treatment with recombinant
TRAIL exhibits a protective role in allergic airway inflammation. Certainly, these
discrepancies could be explained in part by the use of different challenge schedules
with OVA in these studies and/or to a different activity between endogenous
TRAIL expression and recombinant soluble TRAIL. In this respect, in a
completely different setting such as atherosclerosis, while some authors showed
increased levels of TRAIL-positive leukocytes in atherosclerotic plaques and
proposed a role of TRAIL-expressing leukocytes in mediating apoptosis of
vascular smooth cells and plaque destabilization [37], we and other authors have
demonstrated a protective role of exogenous TRAIL for the development of
atherosclerotic lesions [38–40]. Moreover, our current findings underline that the
time/schedule of TRAIL administration has a critical role in determining the
potential effects of recombinant TRAIL. Indeed, in our experimental model we
found optimal activity of TRAIL in preventing the increase of BAL leukocytes
(and down-modulation of CXCL-1/KC) when TRAIL was i.n. instilled 24 hours
before OVA challenges, while the protective effect was attenuated when
recombinant TRAIL was administered at the same time of the OVA challenges.
Thus, while there is no doubt that endogenous TRAIL has a permissive role in the
induction of experimental asthma [4–6, 27], emerging evidences [9], including
our results, suggest that recombinant TRAIL administration can have a protective
role in allergic airway inflammation.
Supporting Information
S1 Figure. Effect of recombinant TRAIL on OVA induced airway inflammation
when administered at the time of OVA challenges. Mice were treated with
recombinant TRAIL at the time of OVA challenges and the cellular influx in the
BAL was assessed. In A, the schedule and the timeline of recombinant TRAIL
treatments with regard to OVA sensitizations/challenges of BALB/c mice are
shown. In B, total cell count of cells present in BAL fluids of Controls, OVA- and
TRAIL+OVA-mice is shown. Horizontal bars are median, upper and lower edges
of box are 75th and 25th percentiles, lines extending from box are 10th and 90th
percentiles; *, P,0.05 (Mann-Whitney rank-sum test).
doi:10.1371/journal.pone.0115387.s001 (TIF)
S2 Figure. Expression of CCL20 and MID-1 in the OVA induced airway
inflammation model. The expression levels of CCL20 (left panel) and MID-1
(right panel) mRNA in lung tissue of Controls, OVA- and TRAIL+OVA-mice
were determined by quantitative RT-PCR. Results from amplifications, done in
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duplicate, are expressed as arbitrary units after normalization for the house-
keeping gene. Horizontal bars are median, upper and lower edges of box are 75th
and 25th percentiles, lines extending from box are 10th and 90th percentiles; *,
P,0.05 (Mann-Whitney rank-sum test).
doi:10.1371/journal.pone.0115387.s002 (TIF)
S1 Table. Levels of cytokines and growth factors analysed by multiplex assay.
doi:10.1371/journal.pone.0115387.s003 (DOCX)
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